Clinical trial · people

MK-677: about 50% more stage IV sleep in young adults on 25 mg

Checked against the paper Clinical trialPublished by PepVault

The takeaway

An early, small trial in healthy people linked short-term MK-677 use to more deep sleep and REM sleep, with no data on longer use.

Kind
Clinical trial
Studied in
People
Published
1997
Journal
Neuroendocrinology

What they tested

The team tested whether taking oral MK-677 for one to two weeks changes sleep quality in healthy young and older adults.

How the study was done

A double-blind, placebo-controlled crossover trial (each person tried every option, in random order) in a small group of healthy adults aged 18-30, who took 5 mg MK-677, 25 mg MK-677 and placebo, a dummy pill, at bedtime for 7 days each, with at least 14 days between periods. A second small group aged 65-71 took 2 mg and then 25 mg at bedtime for 14 days each, with a 14-day washout between, compared against sleep and hormone data taken on the 2 days before treatment and with no placebo period.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the young adults, the 25 mg dose increased stage IV sleep, the deepest sleep stage, by about 50% and REM sleep, the dreaming stage, by more than 20% compared with placebo (p < 0.05). Sleep that strayed from normal patterns dropped from 42% on placebo to 8% on the 25 mg dose (p < 0.03). In the older adults, MK-677 treatment was linked to a nearly 50% increase in REM sleep (p < 0.05), a shorter REM latency, the time it takes to reach the first REM period (p < 0.02), and fewer departures from normal sleep (p < 0.02).

What it doesn’t show

Both groups were very small, the treatment periods lasted only 7 to 14 days, and only healthy people took part. The older group had no placebo period and got the doses in a fixed order, so their results are weaker evidence than the young group's.

The paper

Copinschi et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997.

The compound

More studies on MK-677

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo